Who We Are
Bolt Biotherapeutics, based in the San Francisco Bay Area, is a clinical-stage biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISACs), a new class of immuno-oncology therapeutics. This is a unique opportunity to join and build, with like-minded colleagues, a company that will transform the lives of individuals with cancer.
Reporting to the Vice President, Principal Accounting Officer, this energetic, self-starter will serve as the Director of Technical Accounting to lead our SEC reporting and technical accounting, manage our internal controls and assist in the accounting operations around more complex areas such as R&D accruals, equity, and revenue.
Qualifications
o A demonstrated history of successfully achieving goals, objectives and high performance.
o A positive, self-confident and decisive work ethic with excellent communication skills in both oral and written formats, as well as excellent listening skills.
o A pro-active approach to attacking problems and identifying solutions, displaying initiative and perseverance in order to bring about meaningful change and is open and responsive to new ideas.
o At least 10 years of accounting experience and at least 5 years working in the life science industry.
o In-depth knowledge of GAAP and SEC reporting requirements.
o Excellent analytical, problem-solving, and communication skills.
o High level of accuracy and attention to detail.
o CPA license (active or inactive) required.
This role is a hybrid role. Employees will be in the office at our Redwood City location 1 day a week.
We are an Equal Opportunity Employer offering a competitive salary and benefits package. Applicants should be legally entitled to work for any employer in the US.
Bolt Biotherapeutics requires all U.S. new hires to be fully vaccinated for COVID-19 prior to the first date of employment. As required by applicable law, Bolt will consider requests for Reasonable Accommodations.
Note to Employment Agencies: Please do not forward any agency resumes. The company will not be responsible for any fees related to resumes that are unsolicited.
What We Do
Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. Bolt’s technology is appropriate for a broad spectrum of antibodies targeting tumor antigens expressed on all types of cancer and therefore applicable to many types of patients, including those who are refractory to the current generation of checkpoint inhibitors. The company is led by a team with extensive oncology drug discovery and development experience. Bolt was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University. The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com.
